"ASXL1"-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms

被引：0
|
作者：
Gleitz, Helene F. E. [1 ,2 ]
Schneider, Rebekka K. [1 ,2 ,3 ]
机构：
[1] Erasmus MC, Dept Dev Biol, Rotterdam, Netherlands
[2] Oncode Inst, Erasmus Med Ctr, Rotterdam, Netherlands
[3] Rhein Westfalische TH RWTH Aachen Univ, Inst Biomed Engn, Fac Med, Dept Cell Biol, Aachen, Germany
来源：
HAEMATOLOGICA | 2023年 / 108卷 / 05期
关键词：
STROMAL CELLS;
D O I：
10.3324/haematol.2022.281634
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1203 / 1204
页数：2
相关论文
共 50 条
  • [21] Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates
    Peng Zhang
    Zizhen Chen
    Rong Li
    Ying Guo
    Hui Shi
    Jie Bai
    Hui Yang
    Mengyao Sheng
    Zhaomin Li
    Zhuo Li
    Jianping Li
    Shi Chen
    Weiping Yuan
    Tao Cheng
    Mingjiang Xu
    Yuan Zhou
    Feng-Chun Yang
    Cell Discovery, 4
  • [22] ASXL1 MUTATION IS ASSOCIATED TO LOWER PLATELET COUNTS AND DECREASED BONE MARROW CELLULARITY IN MDS
    Schemenau, J.
    Betz, B.
    Hildebrandt, B.
    Baldus, S.
    Kuendgen, A.
    Neukirchen, J.
    Strupp, C.
    Haas, R.
    Germing, U.
    LEUKEMIA RESEARCH, 2015, 39 : S157 - S157
  • [23] Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms
    Shuhei Asada
    Toshio Kitamura
    International Journal of Hematology, 2019, 110 : 179 - 186
  • [24] DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms
    Haran, Arnon
    Wasserstrom, Avital
    Aumann, Shlomzion
    Vainstein, Vladimir
    Kazoom, Romi
    Jelinek, Batia Roth
    Arad, Ariela
    Buchman, Noa
    Shai, Ela
    Kalish, Yossi
    Gatt, Moshe E.
    Zimran, Eran
    BLOOD, 2024, 144 : 3189 - 3190
  • [25] Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms
    Milica Vukotić
    Sunčica Kapor
    Teodora Dragojević
    Dragoslava Đikić
    Olivera Mitrović Ajtić
    Miloš Diklić
    Tijana Subotički
    Emilija Živković
    Bojana Beleslin Čokić
    Aleksandar Vojvodić
    Juan F. Santibáñez
    Mirjana Gotić
    Vladan P. Čokić
    Experimental & Molecular Medicine, 2022, 54 : 273 - 284
  • [26] Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
    O Abdel-Wahab
    A Pardanani
    J Patel
    M Wadleigh
    T Lasho
    A Heguy
    M Beran
    D G Gilliland
    R L Levine
    A Tefferi
    Leukemia, 2011, 25 : 1200 - 1202
  • [27] Focusing on frequent ASXL1 mutations in myeloid neoplasms, and considering rarer ASXL2 and ASXL3 mutations
    Oak, Jean S.
    Ohgami, Robert S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (04) : 781 - 782
  • [28] Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms
    Vukotic, Milica
    Kapor, Suncica
    Dragojevic, Teodora
    Dikic, Dragoslava
    Ajtic, Olivera Mitrovic
    Diklic, Milos
    Suboticki, Tijana
    Zivkovic, Emilija
    Cokic, Bojana Beleslin
    Vojvodic, Aleksandar
    Santibanez, Juan F.
    Gotic, Mirjana
    Cokic, Vladan P.
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2022, 54 (03): : 273 - 284
  • [29] Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
    Abdel-Wahab, O.
    Pardanani, A.
    Patel, J.
    Wadleigh, M.
    Lasho, T.
    Heguy, A.
    Beran, M.
    Gilliland, D. G.
    Levine, R. L.
    Tefferi, A.
    LEUKEMIA, 2011, 25 (07) : 1200 - 1202
  • [30] Concomitant Analysis of EZH2 and ASXL1 Mutations In Myelofibrosis, Chronic Myelomonocytic Leukemia and Blast-Phase Myeloproliferative Neoplasms
    Abdel-Wahab, Omar
    Pardanani, Animesh
    Patel, Jay
    Lasho, Terra
    Heguy, Adriana
    Levine, Ross
    Tefferi, Ayalew
    BLOOD, 2010, 116 (21) : 1266 - 1266
12345